ravulizumab


( Last Updated : June 23, 2021)
Generic Name:
ravulizumab
Project Status:
Received
Therapeutic Area:
Paroxysmal nocturnal hemoglobinuria
Manufacturer:
Alexion Pharma Canada Corp.
Call for patient/clinician input open:
Brand Name:
Ultomiris
Project Line:
Reimbursement Review
Project Number:
SR0700-000
Call for patient/clinician input closed:

Details


Manufacturer Requested Reimbursement Criteria1:
Ultomiris (ravulizumab for injection) is indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH).
Submission Type:
Initial
Fee Schedule:
Pending
Tumour Type:
N/A
Indications:
Ultomiris (ravulizumab for injection) is indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH).
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input openJune 23, 2021
Call for patient/clinician input closedAugust 16, 2021
Submission receivedJuly 22, 2021
Submission accepted